Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment

    NEXT STORY
    CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program
    PREV STORY
    Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Adherium’s Smartinhaler™ Technology Chosen for Major Asthma Initiative

    MELBOURNE, Australia, Dec. 09, 2016 (GLOBE NEWSWIRE) -- Adherium Limited (ASX:ADR), a global leader ...

    author_avatar
    NASDAQ Market News

    Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting

    author_avatar
    NASDAQ Market News

    Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.

    author_avatar
    NASDAQ Market News